Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase IIa trial to investigate RT-002 (DaxibotulinumtoxinA) for the treatment of plantar fasciitis

Trial Profile

A second phase IIa trial to investigate RT-002 (DaxibotulinumtoxinA) for the treatment of plantar fasciitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Plantar fasciitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jan 2019 According to a Revance Therapeutics media release, patient dosing has been initiated in this study.
    • 07 Jan 2019 Status changed from planning to recruiting, according to a Revance Therapeutics media release.
    • 04 Dec 2018 According to a Revance Therapeutics media release, the company plans to announce first patient dosing before year-end 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top